Lilly Hit By China 2Q Contraction
This article was originally published in PharmAsia News
Executive Summary
Not all pharma multinationals have provided details of their emerging markets performance in the second quarter, but for those that have, it is clear that growth in China has slowed dramatically over the past few months. Lilly was among those to concede to current challenges in this major emerging market, although it remains bullish on long term prospects.